Case Study: Alisept

CASE STUDY 1:

M.S., a 32 year old woman, had a history of reccurent urinary tract infections (UTIs) occurring at least four times per year. After unsuccessful antibiotic therapy, the doctor, after performing an atibiogram, recommends that she use Alisept (3 times at a time) along with antibiotic therapy. This study follows her progress over a six month period with bioassays to quantify new therapies.

The Beginning of Therapy

Beginning: M.S. started taking Alisept (3 capsules per day) along with antibiotic therapy in January 2024.
First week: During the first week, M.S. noticed a decrease in the frequency of the need to urinate and less burning during urination.

Biological Analysis

Before the start of therapy and during the six month period, regular biological analysis including urine culture and urinalysis were performed.

Initial Analysis (January 2024)

Urine culture: Presence of Escherichia coli (E.coli) > 10^5 CFU/ml.
Urine analysis: Increased number of leukocytes (25-50 leukocytes per field), presence of nitrites.

Progress Monitoring

First month (February 2024)

Urine culture: No bacterial growth.
Urine analysis: Normal number of leukocytes (0-5 leukocytes per field), no presence of nitrites.
Clinical signs: No symptoms of urinary infections.

Third month (April 2024)

Urine culture: No bacterial growth.
Urine analysis: Normal number of leukocytes, no presence of nitrites.
Clinical signs: No symptoms of urinary infections.

Sixth month (June 2024)

Urine culture: No bacterial growth.
Urine analysis: Normal number of leukocytes, no presence of nitrites.
Clinical signs: No symptoms of urinary infections.

Conclusion

By using the Alisept supplement, M.S. managed to overcome the problem of recurrent urinary infections. During the six month period, biological analysis showed the absence of pathogenic bacteria and the normalization of urine parameters. She has not had a single episodes of infection, which has significantly improved her daily life. M.S. was satisfied with the results and planned to continue using Alisept as a preventive measure.